News on NGS technologies, RNA-seq, clinical sequencing, & sample prep in genetics, genomics, and molecular diagnostics.
The firm's has expanded its ctDNA sequencing test to cover 17 genes, enough to provide a readout of microsatellite instability for guiding cancer immunotherapy use.
PacBio is looking to increase the yield and reduce the cost of the protocol, which enables long reads and accurate sequencing.
New funding will support assay development and lab space to offer test services, and ultimately a test kit using the firm's resistance database.
Following FDA approval last October, Adaptive has now secured Medicare coverage for its NGS-based minimal residual disease assay, ClonoSeq.
About 77 percent of the species the researchers uncovered in a human microbiome study of more than 9,000 metagenomes had never before been described.
